The abstract shows that antigen-inducible IL18 improves CAR T cell cytotoxicity and in vivo efficacy, but the specific molecular pathways by which IL18 enhances effector functions are not explained. Understanding these mechanisms is critical for optimizing cytokine-engineered CAR T cells for neuroblastoma and other solid cancers. Gap type: unexplained_observation Source paper: Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers. (None, None, PMID:38593230)
Landscape Summary: What mechanisms underlie IL18's enhancement of CAR T cell cytolytic function against solid tumors? is a 0.8 priority gap in cancer immunotherapy. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
What mechanisms underlie IL18's enhancement of CAR T cell cytolytic function against solid tumors? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: